Clinical Trial Update: Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 trial is recruiting to compare tunlametinib capsules with combination chemotherapy in adults with advanced NRAS-mutant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Tunlametinib (tunlametinib)

Snippet

Sponsor: Shanghai Kechow Pharma, Inc. | Conditions: Melanoma | Phase 3 | Status: RECRUITING